BridgeMD
A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy
EU CTIS ID: 2024-519152-82-00
What this study is testing
To evaluate the efficacy of Golca + R vs Investigator’s choice (IC) in participants with Relapsed/Refractory Follicular Lymphoma (R/R FL) with respect to progression-free survival (PFS-IRAC)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants over the age of 18
- Participants meeting all inclusion criteria including disease characteristics, laboratory values and reproductive capacity status would be considered eligible.
You likely can't join if
- Participants cannot participate to the study if they have medical conditions or physical and laboratory test results incompatible with participation in the trial, such as significant medical disease, active infection, laboratory abnormality, incapacitating psychiatric illness
- Other lymphoma subtypes
- Specific allergies or adverse reactions to certain types of medication
The study team makes the final eligibility decision.
Where it's taking place
- Korea, Republic of
- Brazil
- United Kingdom
- Japan
- Turkey
- Saudi Arabia
- Canada
- United Arab Emirates
- United States
- Chile
- Australia
- China
- India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Korea, Republic of; Brazil; United Kingdom; Japan; Turkey; Saudi Arabia and 7 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.